Skip to main content
. Author manuscript; available in PMC: 2015 Aug 19.
Published in final edited form as: Brain Res. 2014 Jun 28;0:21–28. doi: 10.1016/j.brainres.2014.06.026

Fig. 3.

Fig. 3

Changes in mean arterial pressure (MAP) and heart rate (HR) caused by intra-RVLM acetaldehyde (ACA, 2 μg) in the absence and presence of phosphatase inhibitors (0.4 μg okadaic acid, OKA, or 15 pg fostriecin). Values are mean±S.E.M. of 5-10 observations. *P<0.05 vs. “DMSO+ACSF”, +P<0.05 vs. “DMSO+ACA”, #P<0.05 vs. “OKA+ACSF” or “fostriecin+ACSF”.